ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Archives of Disease in Childhood 2008;93:7-10; doi:10.1136/adc.2007.115832
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Balfour-Lynn, I. M
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balfour-Lynn, I. M

Leading articles

Newborn screening for cystic fibrosis: evidence for benefit

Ian M Balfour-Lynn

Correspondence to:
Dr Ian M Balfour-Lynn, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK; i.balfourlynn@ic.ac.uk

Accepted for publication 19 June 2007

The first 150 words of the full text of this article appear below.

Every year our centre is referred children with cystic fibrosis (CF) whose diagnosis has been unnecessarily delayed, having been missed by a number of health professionals. Sometimes the diagnosis is fairly obvious, for example the child has a classic history of frequent chest symptoms, but the loose stools have been put down to frequent courses of antibiotics. Some of these children have irreversible changes and we have even seen bronchiectasis, finger clubbing and mucoid Pseudomonas aeruginosa at presentation. Almost all of these children would have benefited from newborn screening (NBS). Currently, the median age at diagnosis in the UK is 1 month for screened babies and 6 months for those clinically diagnosed (excluding meconium ileus),1 while in the USA it is 2 weeks and 141/2 months, respectively.2

There has been a struggle for CF NBS to gain acceptance. Most supportive evidence comes from the randomised controlled trial in the Wisconsin . . . [Full text of this article]




This article has been cited by other articles:


Home page
Arch. Dis. Child.Home page
F Festini, G Taccetti, V Galici, S Campana, G Mergni, and T Repetto
Long-term health outcomes of neonatal screening for cystic fibrosis
Arch. Dis. Child., April 1, 2008; 93(4): 357 - 358.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health